share_log

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

Benzinga ·  Nov 11, 2024 16:50  · Ratings

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment